Thalidomide Suppresses Angiogenesis Through the Signal Transducer and Activator of Transcription 3/SP4 Signaling Pathway in the Peritoneal Membrane
Peritoneal angiogenesis is the key pathophysiological factor that limits peritoneal ultrafiltration during peritoneal dialysis (PD) in uremic patients. Thalidomide has been confirmed to inhibit angiogenesis by inhibiting the secretion of vascular endothelial growth factor (VEGF), but the exact mecha...
Main Authors: | Nan Zhu, Ling Wang, Huimin Guo, Jieshuang Jia, Lijie Gu, Xuan Wang, Man Yang, Haochen Guan, Weijie Yuan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2021.712147/full |
Similar Items
-
Thalidomide failed to inhibit angiogenesis and fibrosis in hepatic schistosomiasis of the mouse
by: Camila Bião Lima, et al.
Published: (2007-11-01) -
Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
by: Priscilla Cury de Camargo Cury, et al.
Published: (2020-04-01) -
Angiogenesis and Inflammation in Peritoneal Dialysis: The Role of Adipocytes
by: Jun Shi, et al.
Published: (2017-05-01) -
Tetramethylpyrazine Ameliorates Peritoneal Angiogenesis by Regulating VEGF/Hippo/YAP Signaling
by: Xiaolin Zhu, et al.
Published: (2021-04-01) -
Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis
by: Yingfeng Shi, et al.
Published: (2020-01-01)